



West Nile Virus Disease

Guest Editors:

Dr. Parminder J.S. Vig

Neurology Research Division,
Professor of Neurology and
Biochemistry, Department of
Neurology, University of
Mississippi Medical Center, 2500
North State Street, Jackson, MS
39216, USA

Prof. Dr. Fengwei Bai

Cell and Molecular Biology
Program, University of Southern
Mississippi, Hattiesburg, MS
39406, USA

Deadline for manuscript
submissions:

closed (31 December 2020)

Message from the Guest Editors

Dear Colleagues,

West Nile virus (WNV) is the most common mosquito-borne virus in North America. WNV can enter the central nervous system (CNS) and cause WN neuroinvasive disease (WNND) with less understood long term consequences. An association between the WN infection and myasthenia gravis was recently observed in patients long after they recovered from WNND and no prior history of myasthenia gravis. The exact reason for the long-term lingering symptoms after WNV infection are still not well characterized. Therefore, we would like to encourage submission of articles to this special issue, which will cover recent advances in understanding the mechanisms of WNV invasion/infection and neurodegeneration in the CNS, the cause of WNND and reasons for lingering neurological symptoms. Identification of novel therapeutic drugs/peptides, which can suppress the pathologic phenotype is important, articles on this topic are also welcome.

Dr. Parminder J.S. Vig

Dr. Fengwei Bai

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com